Comparison of the effectiveness of Escitalopram and Bupropion in treatment of depression symptome patient with heart failure in double blind randomized clinical trial

Determining the comparative effectiveness of escitalopram and bupropion in the treatment of depression in patients with heart failure

Clinical trial without control group, with parallel groups, double-blind, randomized, 80 patients with a block size of 4 will be randomly assigned to two groups of 40 people

The studied population is patients over 18 years of age referring to heart failure clinics of Babol University of Medical Sciences. Patients will be randomly divided into 2 intervention groups. The first intervention group is Bupropion treatment group and the second intervention group is Escitalopram treatment group. Bupropion and Escitalopram are prepared and coded in completely similar containers without name labels, which are prepared and coded in the same color and smell, and are provided to the researcher based on random allocation by the statistician of the project. Patients will be visited four times.

Inclusion criteria: age over 18 years, heart failure, willingness to participate in the research, depression disorder according to the questionnaire, exclusion criteria: patient with cognitive impairment, mental retardation, history of drug use, bipolar disorder, History of depression before heart failure, history of seizures

Intervention group 1: Bupropion (Zibutrin) (Tehran Daru pharmaceutical group) (75 mg) starts as 1 tablet daily (which can be increased up to a maximum of 150 mg according to the clinical response and side effects) Intervention group 2: Citalopram Tekaje drug group (5 mg) starts as 1 tablet daily (which can be increased up to a maximum of 20 mg according to the clinical response and side effects)

Patient´s depressive condition

Patients will be randomly assigned to two groups of 40 people using blocks of 4 and a ratio of 1:1. Randomization will be done using Statistics and Sample Size android software. In order to hide the treatment process, each drug is assigned a random code corresponding to the sequence generated above, and only the random code is written on the cans of the drugs. After entering the patients into the study and assigning treatment to them, the code inserted on the medicine will be recorded on the patient's file

Bupropion (Zibutrin) (Tehran Daro Pharmaceutical Group) and Citalopram (Takajeh Pharmaceutical Group) in completely similar containers without name labels, which are prepared and coded in the same color and smell, and are provided to the researcher based on random allocation by the project statistics expert. Takes. Therefore, none of the patients and the researcher will know about the assigned treatment and will not know until the end of the study. Codes are opened at the end of the study or in special cases with the diagnosis of the treating physician (in case of severe drug side effects) during the study.